Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.41 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26122244 | 1.00 | PARP1 (0.46) | PARP1PRMT5WDR77PRAP1ROCK1 | |
| SCHEMBL26120440 | 0.91 | PARP1 (0.49) | PARP1PRMT5WDR77PRAP1 | |
| SCHEMBL30546371 | 0.91 | PARP1 (0.49) | PARP1PRMT5WDR77PRAP1 | |
| SCHEMBL10039742 | 0.84 | PARP1 (0.57) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL30546280 | 0.81 | PARP1 (0.57) | PARP1PRAP1 | |
| SCHEMBL26124497 | 0.81 | PARP1 (0.47) | PARP1PRMT5WDR77PRAP1CYP3A4 | |
| SCHEMBL26123532 | 0.81 | PARP1 (0.57) | PARP1PRAP1 | |
| SCHEMBL26125985 | 0.80 | PARP1 (0.51) | PARP1PRMT5WDR77PRAP1 | |
| SCHEMBL30546130 | 0.78 | PRMT5 (0.44) | PARP1PRMT5WDR77PRAP1 | |
| SCHEMBL30546282 | 0.78 | PRMT5 (0.44) | PARP1PRMT5WDR77PRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |